Linc01614 Regulates the Proliferation, Apoptosis, and Chemotherapy Resistance in Esophageal Squamous Cell Carcinoma by Targeting Mir-4775
,
Abstract
Background: Esophageal squamous cell carcinoma (ESCC), a widely known esophageal disease, severely affects people's health. Numerous investigations demonstrated that long non-coding RNAs (lncRNAs) performed key jobs inside a wide scope of organic cycles and stand out in malignant growth. Our study planned to investigate the roles and mechanisms of linc01614 in ESCC.
Methods: A Total of 60 ESCC tissue samples including 30 patients with cisplatin sensitivity and 30 patients with cisplatin resistance, who received DDP-based treatment, were obtained from Zhuhai People's Hospital, Zhuhai City during 2021. These tissues were frozen and saved in a -80 ℃ ultra-low temperature freezer. We performed CCK-8, clone formation, flow cytometry assays to determine the effect of linc01614 on ESCC progression, and explored the specific mechanism of linc01614 in ESCC cell proliferation, apoptosis, and chemotherapy resistance.
Results: linc01614 expression was upregulated in ESCC tissues and cells compared with non-tumor tissues and human normal esophageal epithelial cells (Het-1A). Knockdown of linc01614 repressed cell expansion, chemotherapy opposition, and advanced cell apoptosis in ESCC. Besides, linc01614 regulated the expression of miR-4775 as a competitive endogenous RNA (ceRNA).
Conclusion: The linc01614/miR-4775 axis played an important role in ESCC progression and drug resistance, revealing that linc01614 is a promising target in ESCC treatment.
1. Nagai H, Kim YH (2017). Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis, 9(3):448-451.
2. Zang B, Zhao J, Chen C (2019). LncRNA PCAT-1 Promoted ESCC Progression via Regulating ANXA10 Expression by Sponging miR-508-3p. Cancer Manag Res, 11:10841-10849.
3. Zeng RJ, Zheng CW, Gu JE, et al (2019). RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes. Mol Oncol, 13(9):2010-2030.
4. Liu B, Wang C, Chen P, Cheng B, Cheng Y (2018). RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression. Onco Targets Ther, 11:211-220.
5. Huarte M (2015). The emerging role of lncRNAs in cancer. Nat Med, 21(11):1253-61.
6. Zong MZ, Shao Q, An XS (2019). Expression and prognostic significance of long noncoding RNA AK001796 in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci, 23(1):181-186.
7. Hu HB, Jie HY, Zheng XX (2016). Three Circulating LncRNA Predict Early Progress of Esophageal Squamous Cell Carcinoma. Cell Physiol Biochem, 40(1-2):117-125.
8. Liu AN, Qu HJ, Yu CY, Sun P (2018). Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. J Cell Mol Med, 22(9):4034-4044.
9. Wang H, Wu J, Guo W (2020). SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12. Onco Targets Ther, 13:4305-4318.
10. Sun Y, Ling C (2019). Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer. Medicine (Baltimore), 98(30):e16437.
11. Wang Y, Song B, Zhu L, Zhang X (2019). Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. PeerJ, 7:e7976.
12. Vishnubalaji R, Shaath H, Elkord E, Alajez NM (2019). Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFbeta and focal adhesion kinase (FAK) signaling. Cell Death Discov, 5:109.
13. Jia Y, Tian C, Wang H, et al (2021). Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin. Mol Cancer, 20(1):162.
14. Cheng J, Zhang R, Yan M, Li Y (2022). Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma. BMC Cancer, 22(1):238.
15. Kubo Y, Tanaka K, Masuike Y, et al (2022). Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells. J Transl Med, 20(1):383.
16. Zheng TL, Li DP, He ZF, Zhao S (2019). miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int, 19:250.
17. Yu L, Gu C, Zhong D, et al (2014). Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett, 355(1):34-45.
18. Wang D, Zhang H, Fang X, Cao D, Liu H (2020). Pan-cancer analysis reveals the role of long non-coding RNA LINC01614 as a highly cancer-dependent oncogene and biomarker. Oncol Lett, 20(2):1383-1399.
19. Alfarouk KO, Stock CM, Taylor S, et al (2015). Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int, 15:71.
20. Ren J, Ding L, Zhang D, et al. (2018) Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics, 8(14):3932-3948.
21. Han P, Li JW, Zhang BM, et al (2017). The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. Mol Cancer, 16(1):9.
22. Li Y, Li C, Li D, Yang L, Jin J, Zhang B (2019). lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther, 12:2649-2660.
23. Zhen Q, Gao LN, Wang RF, et al (2018). LncRNA PCAT-1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin. Cell Biochem Funct, 36(1):27-33.
24. Kang M, Ren M, Li Y, Fu Y, Deng M, Li C (2018). Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res, 37(1):171.
25. Hu M, Zhang Q, Tian XH, Wang JL, Niu YX, Li G (2019). lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. Mol Carcinog, 58(12):2207-2217.
26. Tong Y, Yang L, Yu C, et al (2020). Tumor-Secreted Exosomal lncRNA POU3F3 Promotes Cisplatin Resistance in ESCC by Inducing Fibroblast Differentiation into CAFs. Mol Ther Oncolytics, 18:1-13.
27. Xu C, Guo Y, Liu H, Chen G, Yan Y, Liu T (2018). TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Cell Biosci, 8:61.
28. Yang C, Shen S, Zheng X, et al (2020). Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4. FASEB J, 34(5):6055-6069.
29. Wang L, Yu X, Zhang Z, et al (2017). Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. J Exp Clin Cancer Res, 36(1):182.
30. Zhao S, Sun H, Jiang W, et al (2017). miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFbeta-mediated epithelial to mesenchymal transition. Mol Cancer, 16(1):12.
31. Liu Y, Fan X, Zhao Z, Shan X (2020). LncRNA SLC7A11-AS1 Contributes to Lung Cancer Progression Through Facilitating TRAIP Expression by Inhibiting miR-4775. Onco Targets Ther, 13:6295-6302.
32. Zhu Z, Dai J, Liao Y, Ma J, Zhou W (2018). Knockdown of Long Noncoding RNA LINC00152 Suppresses Cellular Proliferation and Invasion in Glioma Cells by Regulating miR-4775. Oncol Res, 26(6):857-867.
2. Zang B, Zhao J, Chen C (2019). LncRNA PCAT-1 Promoted ESCC Progression via Regulating ANXA10 Expression by Sponging miR-508-3p. Cancer Manag Res, 11:10841-10849.
3. Zeng RJ, Zheng CW, Gu JE, et al (2019). RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes. Mol Oncol, 13(9):2010-2030.
4. Liu B, Wang C, Chen P, Cheng B, Cheng Y (2018). RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression. Onco Targets Ther, 11:211-220.
5. Huarte M (2015). The emerging role of lncRNAs in cancer. Nat Med, 21(11):1253-61.
6. Zong MZ, Shao Q, An XS (2019). Expression and prognostic significance of long noncoding RNA AK001796 in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci, 23(1):181-186.
7. Hu HB, Jie HY, Zheng XX (2016). Three Circulating LncRNA Predict Early Progress of Esophageal Squamous Cell Carcinoma. Cell Physiol Biochem, 40(1-2):117-125.
8. Liu AN, Qu HJ, Yu CY, Sun P (2018). Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. J Cell Mol Med, 22(9):4034-4044.
9. Wang H, Wu J, Guo W (2020). SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12. Onco Targets Ther, 13:4305-4318.
10. Sun Y, Ling C (2019). Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer. Medicine (Baltimore), 98(30):e16437.
11. Wang Y, Song B, Zhu L, Zhang X (2019). Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. PeerJ, 7:e7976.
12. Vishnubalaji R, Shaath H, Elkord E, Alajez NM (2019). Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFbeta and focal adhesion kinase (FAK) signaling. Cell Death Discov, 5:109.
13. Jia Y, Tian C, Wang H, et al (2021). Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin. Mol Cancer, 20(1):162.
14. Cheng J, Zhang R, Yan M, Li Y (2022). Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma. BMC Cancer, 22(1):238.
15. Kubo Y, Tanaka K, Masuike Y, et al (2022). Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells. J Transl Med, 20(1):383.
16. Zheng TL, Li DP, He ZF, Zhao S (2019). miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int, 19:250.
17. Yu L, Gu C, Zhong D, et al (2014). Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett, 355(1):34-45.
18. Wang D, Zhang H, Fang X, Cao D, Liu H (2020). Pan-cancer analysis reveals the role of long non-coding RNA LINC01614 as a highly cancer-dependent oncogene and biomarker. Oncol Lett, 20(2):1383-1399.
19. Alfarouk KO, Stock CM, Taylor S, et al (2015). Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int, 15:71.
20. Ren J, Ding L, Zhang D, et al. (2018) Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics, 8(14):3932-3948.
21. Han P, Li JW, Zhang BM, et al (2017). The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. Mol Cancer, 16(1):9.
22. Li Y, Li C, Li D, Yang L, Jin J, Zhang B (2019). lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther, 12:2649-2660.
23. Zhen Q, Gao LN, Wang RF, et al (2018). LncRNA PCAT-1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin. Cell Biochem Funct, 36(1):27-33.
24. Kang M, Ren M, Li Y, Fu Y, Deng M, Li C (2018). Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res, 37(1):171.
25. Hu M, Zhang Q, Tian XH, Wang JL, Niu YX, Li G (2019). lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. Mol Carcinog, 58(12):2207-2217.
26. Tong Y, Yang L, Yu C, et al (2020). Tumor-Secreted Exosomal lncRNA POU3F3 Promotes Cisplatin Resistance in ESCC by Inducing Fibroblast Differentiation into CAFs. Mol Ther Oncolytics, 18:1-13.
27. Xu C, Guo Y, Liu H, Chen G, Yan Y, Liu T (2018). TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Cell Biosci, 8:61.
28. Yang C, Shen S, Zheng X, et al (2020). Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4. FASEB J, 34(5):6055-6069.
29. Wang L, Yu X, Zhang Z, et al (2017). Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. J Exp Clin Cancer Res, 36(1):182.
30. Zhao S, Sun H, Jiang W, et al (2017). miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFbeta-mediated epithelial to mesenchymal transition. Mol Cancer, 16(1):12.
31. Liu Y, Fan X, Zhao Z, Shan X (2020). LncRNA SLC7A11-AS1 Contributes to Lung Cancer Progression Through Facilitating TRAIP Expression by Inhibiting miR-4775. Onco Targets Ther, 13:6295-6302.
32. Zhu Z, Dai J, Liao Y, Ma J, Zhou W (2018). Knockdown of Long Noncoding RNA LINC00152 Suppresses Cellular Proliferation and Invasion in Glioma Cells by Regulating miR-4775. Oncol Res, 26(6):857-867.
| Files | ||
| Issue | Vol 52 No 6 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i6.12959 | |
| Keywords | ||
| Linc01614 Apoptosis Drug resistance | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Wei W, Wei X, Xie X. Linc01614 Regulates the Proliferation, Apoptosis, and Chemotherapy Resistance in Esophageal Squamous Cell Carcinoma by Targeting Mir-4775. Iran J Public Health. 2023;52(6):1170-1180.
